Tensions between Japan and South Korea come as the U.S. and its trading partners are embroiled in a global trade war.Technologyread more
The one-to-eight stock split would mean the current number of ordinary shares — which stands at 4 billion — will increase to 32 billion. It comes ahead of a reported Hong Kong...Asia Marketsread more
Minutes from the Reserve Bank of Australia's monetary policy meeting in July showed the central bank was ready to adjust interest rates if required.Asia Marketsread more
Current and former Tesla employees working in the company's open-air "tent" factory say they felt pressure to take shortcuts to hit aggressive Model 3 production goals,...Technologyread more
China's fiscal spending increased 10.7% in the first six months from a year earlier, the finance ministry said on Tuesday, underlining the government's bid to support the...China Economyread more
Von der Leyen, one of the longest serving ministers in Germany, has tried to woo European lawmakers over the last two weeks.Europe Newsread more
The findings by McKinsey and Company come amid a year-long tariff fight between the U.S. and China, which has spilled into areas such as technology and security.China Economyread more
Microsoft's considerable reach into the corporate world isn't something Slack CEO Stewart Butterfield is very concerned about.Technologyread more
A devastating outbreak of African swine fever that has killed millions of pigs in China is changing attitudes in a country where farm hygiene has often been seen as lax by...Livestockread more
In a closed-door meeting at a Manhattan mansion, executives outlined changes to controversial software that was implicated in two crashes.Aerospace & Defenseread more
President Donald Trump and the RNC are picking up key supporters in the business community who did not back him as a candidate in 2016.2020 Electionsread more
Jim Cramer thinks that once the numbers for February are released, investors may be surprised to find out that last month was weaker than a lot of people expected.
Additionally the "Mad Money" host has a bearish outlook for the next few weeks in March, as anxious investors prepare for the Fed meeting on March 17.
With this in mind, what stocks does Cramer think will be winners in a weak economy? Biotechs.
"If February was as weak as I think it was in this country, then the biotechs, which perform well when the economy takes a hit, will only gather steam over the next few weeks," Cramer said.
First up on Cramer's radar is Gilead. Yes, it has been a major battleground lately. But it still only trades at 12 times earnings, and it has been able to maintain stability and stay above $100 on the downside.
Next up is Biogen Idec, which has Alzheimer's data coming out on March 20. Cramer thinks this could be a good catalyst to take the stock even higher.
Speaking of blockbuster drugs, Regeneron has been stalled lately, but that hasn't pushed Cramer away. He reminded investors to maintain focus on the anticholesterol drug in its pipeline, which has many cardiologists excited.
In the emerging biotech field, Cramer thinks Isis Pharma has such a strong pipeline that there will be positive news ahead. And while the stock is heavily shorted currently, the amazing product horizon and strong CEO give Cramer faith.
Read more from Mad Money with Jim Cramer
Cramer: This capitalizes on Lumber Liquidators
Cramer: 6 worries that could turn into disaster
Cramer: Fed may bring major turmoil
Finally, Cramer thinks Alkermes is a steal at these prices right now. It had wonderful results released surrounding antidepression treatments, and if history tells us anything, it is that Alkermes tends to be a winner when it has broken down.
"Can biotech lead us out of this morass? Not alone…I can only say there are a lot of ways to win here, either with a takeout on the medium-sized companies, or out-year earnings power for the larger biotechs," Cramer said.